uniQure (NASDAQ:QURE) Price Target Increased to $10.00 by Analysts at The Goldman Sachs Group

uniQure (NASDAQ:QURE) had its price objective hoisted by The Goldman Sachs Group from $6.00 to $10.00 in a research note released on Friday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biotechnology company’s stock.

Several other brokerages have also recently commented on QURE. Mizuho reduced their price target on uniQure from $7.00 to $6.00 and set a neutral rating for the company in a research report on Wednesday, May 8th. Cantor Fitzgerald reaffirmed an overweight rating and set a $24.00 target price on shares of uniQure in a research report on Tuesday, July 16th. Finally, HC Wainwright reissued a buy rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $18.60.

uniQure Price Performance

Shares of QURE stock opened at $7.58 on Friday. The stock has a 50 day moving average of $6.02 and a two-hundred day moving average of $5.53. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The company has a market capitalization of $368.01 million, a P/E ratio of -1.22 and a beta of 0.97.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). The business had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 137.05%. As a group, equities analysts expect that uniQure will post -4.4 EPS for the current year.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 222.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 4,315 shares during the period. SG Americas Securities LLC purchased a new stake in uniQure in the 2nd quarter valued at about $79,000. Vanguard Personalized Indexing Management LLC purchased a new stake in uniQure in the 4th quarter valued at about $86,000. Virtu Financial LLC purchased a new stake in shares of uniQure in the 4th quarter worth approximately $195,000. Finally, Clear Harbor Asset Management LLC raised its stake in shares of uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after acquiring an additional 12,500 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.